Smith & Nephew SNATS, Inc. (SNN): Price and Financial Metrics
Smith & Nephew SNATS, Inc. (SNN)
Today's Latest Price: $38.98 USD
Updated Nov 27 5:00pm
Add SNN to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 143 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
SNN Stock Summary
- Smith & Nephew Plc's market capitalization of $17,252,691,700 is ahead of 88.78% of US-listed equities.
- With a year-over-year growth in debt of 38.31%, Smith & Nephew Plc's debt growth rate surpasses 78.41% of about US stocks.
- The volatility of Smith & Nephew Plc's share price is greater than that of merely 5.04% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to Smith & Nephew Plc are STE, GIB, BRO, ROL, and COO.
- SNN's SEC filings can be seen here. And to visit Smith & Nephew Plc's official web site, go to www.smith-nephew.com.
SNN Stock Price Chart Interactive Chart >
SNN Price/Volume Stats
| Current price | $38.98 | 52-week high | $52.26 |
| Prev. close | $37.96 | 52-week low | $26.07 |
| Day low | $38.36 | Volume | 261,232 |
| Day high | $39.00 | Avg. volume | 599,912 |
| 50-day MA | $38.56 | Dividend yield | 1.44% |
| 200-day MA | $39.70 | Market Cap | 17.07B |
Smith & Nephew SNATS, Inc. (SNN) Company Bio
Smith & Nephew plc develops, manufactures, markets, and sells medical devices in the advanced surgical devices and advanced wound management sectors worldwide. The Company operates in two segments: Advanced Surgical Devices and Advanced Wound Management. The company was founded in 1856 and is based in London, the United Kingdom.
SNN Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $38.98 | $13.75 | -65% |
We started the process of determining a valid price forecast for Smith & Nephew Plc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Smith & Nephew Plc ranked in the 24th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Smith & Nephew Plc ended up being:
- As a business, SNN is generating more cash flow than 78.67% of positive cash flow stocks in the Healthcare.
- The business' balance sheet suggests that 6% of the company's capital is sourced from debt; this is greater than merely 16.4% of the free cash flow producing stocks we're observing.
- SNN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 42.65% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -66% |
| 1% | -65% |
| 2% | -65% |
| 3% | -65% |
| 4% | -64% |
| 5% | -64% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as SNN, try ABC, LGND, RMD, VIVO, and A.
Loading social stream, please wait...